Although bone metastases from prostate cancer are described as osteoblastic, markers of both osteoblastic and osteoclastic activity are strikingly elevated in men with metastatic prostate cancer. Elevated markers of osteoblastic and osteoclastic activity are associated with adverse clinical outcomes in men with prostate cancer--outcomes including shorter time to skeletal complications, disease progression, and death. Bone marker measurement appears to be a promising method for monitoring the efficacy of bone-targeted therapy. Additional studies are needed to assess the potential role of bone markers in identifying men at highest risk for development of bone metastases.

中文翻译：

---

前列腺癌中骨代谢的标志物。

尽管前列腺癌的骨转移被描述为成骨细胞，但是在患有转移性前列腺癌的男性中，成骨细胞和破骨细胞活性的标志物明显升高。成骨细胞和破骨细胞活性标记升高与前列腺癌男性不良临床结局相关-结果包括缩短骨骼并发症的时间，疾病进展和死亡。骨标记物测量似乎是监测骨靶向疗法疗效的一种有前途的方法。还需要进行其他研究来评估骨标记物在确定骨转移发生风险最高的男性中的潜在作用。